Sandoz files biosimilar of Amgen osteoporosis drug in US

Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to file for approval of a copycat version of the blockbuster drug.